$839.16 Million in Sales Expected for Black Diamond Therapeutics (NASDAQ:REYN) This Quarter

Equities analysts predict that Black Diamond Therapeutics (NASDAQ:REYN) will announce $839.16 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Black Diamond Therapeutics’ earnings. The highest sales estimate is $874.80 million and the lowest is $815.38 million. The company is expected to report its next earnings results on Thursday, August 6th.

On average, analysts expect that Black Diamond Therapeutics will report full-year sales of $3.21 billion for the current financial year, with estimates ranging from $3.17 billion to $3.28 billion. For the next financial year, analysts anticipate that the company will report sales of $3.26 billion, with estimates ranging from $3.18 billion to $3.35 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Black Diamond Therapeutics.

Black Diamond Therapeutics (NASDAQ:REYN) last announced its earnings results on Thursday, May 7th. The company reported $0.30 EPS for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.03. The company had revenue of $691.00 million during the quarter, compared to the consensus estimate of $695.40 million. The firm’s quarterly revenue was up 10.6% on a year-over-year basis.

A number of equities analysts recently commented on the company. Citigroup raised their target price on Black Diamond Therapeutics from $33.00 to $41.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $31.00 target price on shares of Black Diamond Therapeutics in a report on Monday, March 9th. Zacks Investment Research raised Black Diamond Therapeutics from a “hold” rating to a “buy” rating and set a $38.00 target price on the stock in a report on Friday, May 8th. Barclays reissued a “hold” rating and set a $34.00 price target on shares of Black Diamond Therapeutics in a report on Sunday, May 10th. Finally, Stifel Nicolaus raised their price target on Black Diamond Therapeutics from $38.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Black Diamond Therapeutics currently has an average rating of “Buy” and an average price target of $36.60.

Black Diamond Therapeutics stock traded up $0.59 during trading on Monday, reaching $34.89. The company had a trading volume of 332,481 shares, compared to its average volume of 851,251. Black Diamond Therapeutics has a 52 week low of $21.61 and a 52 week high of $36.00. The business’s 50-day moving average is $33.64. The stock has a market capitalization of $7.32 billion and a price-to-earnings ratio of 24.06.

Institutional investors have recently modified their holdings of the company. American International Group Inc. purchased a new position in shares of Black Diamond Therapeutics during the first quarter valued at about $26,000. Oppenheimer Asset Management Inc. purchased a new position in shares of Black Diamond Therapeutics during the first quarter valued at about $29,000. Advisor Group Holdings Inc. purchased a new position in shares of Black Diamond Therapeutics during the first quarter valued at about $41,000. Global Retirement Partners LLC purchased a new position in shares of Black Diamond Therapeutics during the first quarter valued at about $41,000. Finally, Deutsche Bank AG purchased a new position in shares of Black Diamond Therapeutics during the first quarter valued at about $67,000. Hedge funds and other institutional investors own 25.13% of the company’s stock.

Black Diamond Therapeutics Company Profile

Reynolds Consumer Products Inc, a consumer products company, produces and sells products across cooking, waste and storage, and tableware. It operates through four segments: Reynolds Cooking & Baking, Hefty Waste & Storage, Hefty Tableware, and Presto Products. The Reynolds Cooking & Baking segment produce foil, parchment paper, and disposable aluminum pans, as well as cooker liners.

Featured Story: High-Yield Dividend Stocks

Get a free copy of the Zacks research report on Black Diamond Therapeutics (REYN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Black Diamond Therapeutics (NASDAQ:REYN)

Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.